Papp L Roy & Associates Has $612,000 Holdings in PAREXEL International Co. (PRXL)

Papp L Roy & Associates trimmed its holdings in shares of PAREXEL International Co. (NASDAQ:PRXL) by 75.5% in the third quarter, according to its most recent filing with the SEC. The firm owned 6,950 shares of the medical research company’s stock after selling 21,382 shares during the period. Papp L Roy & Associates’ holdings in PAREXEL International were worth $612,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in the company. World Asset Management Inc lifted its holdings in shares of PAREXEL International by 0.3% during the 2nd quarter. World Asset Management Inc now owns 3,212 shares of the medical research company’s stock worth $279,000 after acquiring an additional 9 shares during the period. 1st Global Advisors Inc. lifted its holdings in PAREXEL International by 0.4% during the 2nd quarter. 1st Global Advisors Inc. now owns 5,391 shares of the medical research company’s stock valued at $469,000 after purchasing an additional 21 shares during the last quarter. Amalgamated Bank lifted its holdings in PAREXEL International by 0.6% during the 2nd quarter. Amalgamated Bank now owns 7,259 shares of the medical research company’s stock valued at $631,000 after purchasing an additional 42 shares during the last quarter. Public Employees Retirement System of Ohio lifted its holdings in PAREXEL International by 4.5% during the 1st quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock valued at $108,000 after purchasing an additional 73 shares during the last quarter. Finally, Texas Permanent School Fund lifted its holdings in PAREXEL International by 0.5% during the 2nd quarter. Texas Permanent School Fund now owns 37,062 shares of the medical research company’s stock valued at $3,221,000 after purchasing an additional 169 shares during the last quarter. 87.45% of the stock is owned by institutional investors.

Shares of PAREXEL International Co. (NASDAQ:PRXL) traded down $0.02 during midday trading on Wednesday, reaching $88.08. 7,021,100 shares of the company were exchanged, compared to its average volume of 1,041,144. The company has a quick ratio of 1.45, a current ratio of 1.45 and a debt-to-equity ratio of 1.01. PAREXEL International Co. has a 52-week low of $51.16 and a 52-week high of $88.10.

PAREXEL International (NASDAQ:PRXL) last issued its quarterly earnings data on Monday, August 28th. The medical research company reported $1.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.94 by $0.08. PAREXEL International had a net margin of 4.62% and a return on equity of 19.95%. The firm had revenue of $557.20 million during the quarter, compared to analysts’ expectations of $537.59 million. During the same quarter in the previous year, the company earned $0.94 earnings per share.

TRADEMARK VIOLATION WARNING: “Papp L Roy & Associates Has $612,000 Holdings in PAREXEL International Co. (PRXL)” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://ledgergazette.com/2017/11/22/papp-l-roy-associates-reduces-position-in-parexel-international-co-prxl.html.

Several equities analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of PAREXEL International from a “buy” rating to a “hold” rating in a report on Thursday, August 17th. BidaskClub cut shares of PAREXEL International from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $80.76.

PAREXEL International Company Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Institutional Ownership by Quarter for PAREXEL International (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply